Investigation of the 12-month efficacy and safety of low-dose mifepristone in the treatment of painful adenomyosis
Reproductive and Developmental Medicine · 2022-09 · 6 (3) · 152-161
DOI: 10.1097/rd9.0000000000000031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive and Developmental Medicine, online erschienen am 30.09.2022. Verfasst von Shu-Yi Chen und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To study the 12-month effects and possible mechanisms of low-dose mifepristone in the treatment of adenomyosis.
Methods
Patients included in this retrospective study had painful adenomyosis and previously received 5 mg mifepristone daily (group A, n = 45) or 5 mg mifepristone daily with a poor-effect levonorgestrel-releasing intrauterine device (group B, n = 13) for 12 months. Uterine size, serum CA125 levels, estradiol levels, Visual Analogue Scale (VAS) score, endometrial thickness, and hemoglobin levels were compared before and after treatment and investigated again at 3 to 6 months after drug withdrawal. Another 8 patients with adenomyosis (group C, n = 8) who underwent surgery for severe dysmenorrhea during the same period were only used as a control group for immunohistochemical research. Endometrial biopsy results and expression of nerve growth factor (NGF), cyclooxygenase-2 (COX-2), and nuclear-associated antigen Ki-67 (Ki-67) in endometrial tissues and adenomyotic lesions were also analyzed.
Results
The VAS scores in both experimental groups at all time points during treatment and follow-up were significantly lower ( P
Zitieren
APA
Chen, S., Zhao, M., Sun, W., Zhu, L., & Zhang, X. (2022). Investigation of the 12-month efficacy and safety of low-dose mifepristone in the treatment of painful adenomyosis. Reproductive and Developmental Medicine, 6(3), 152-161. https://doi.org/10.1097/rd9.0000000000000031
Vancouver
Chen S, Zhao M, Sun W, Zhu L, Zhang X. Investigation of the 12-month efficacy and safety of low-dose mifepristone in the treatment of painful adenomyosis. Reproductive and Developmental Medicine. 2022;6(3):152-161. doi:10.1097/rd9.0000000000000031
BibTeX
@article{Chen2022,
author = {Chen, Shu-Yi and Zhao, Meng-Dan and Sun, Wen-Ting and Zhu, Li-Bo and Zhang, Xin-Mei},
title = {Investigation of the 12-month efficacy and safety of low-dose mifepristone in the treatment of painful adenomyosis},
journal = {Reproductive and Developmental Medicine},
year = {2022},
volume = {6},
number = {3},
pages = {152--161},
doi = {10.1097/rd9.0000000000000031}
}
EUVIMED